Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and ...

There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients. The treatment of chronic lymphocytic leukemia (CLL) has evolved ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

Jaypirca showed higher ORR than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL patients, with 87% vs. 78.5% overall. Progression-free survival trends favored Jaypirca, particularly ...

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie, in collaboration with Hoffmann-La Roche and the ...

Patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who received pirtobrutinib (Jaypirca; Eli Lilly) monotherapy showed an 80% reduction in progression ...

People infected with HIV must take antiretroviral drugs for life. But promising trials using engineered antibodies suggest that "functional cures" may be in reach. When you purchase through links on ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus for certain participants in recent trials in Africa and Europe A digital ...

For the first time since HIV was identified, early human trials are starting to show what long‑imagined “drug‑free control” of the virus might look like in practice. Instead of chasing a total ...